Skip to main content

Psychosis

5
Pipeline Programs
17
Companies
21
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
1
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 22 programs with unclassified modality

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
1
CBD 100 mg/mL Oral SolutionPhase 31 trial
Active Trials
NCT06778564Not Yet Recruiting250Est. Feb 2029
Laza Medical
Laza MedicalCA - Campbell
1 program
1
AspirinPhase 2/31 trial
Active Trials
NCT02685748Completed60Est. Dec 2019
Alliance Pharmaceuticals
3 programs
1
ceftriaxonePhase 1/21 trial
Care CoordinationN/A1 trial
Low Intensity InterventionN/A1 trial
Active Trials
NCT06071858Recruiting350Est. Oct 2028
NCT03610087Completed70Est. Jun 2020
NCT00591318Terminated12Est. Mar 2011
Innovation Pharmaceuticals
4 programs
1
Behavioral/Attitudinal OnTrack Role-Playing GamePhase 11 trial
CSC OnDemandN/A1 trial
CSC OnDemand Training InterventionN/A1 trial
OnTrack>TheGameN/A1 trial
Active Trials
NCT02933567Completed16Est. Aug 2017
NCT03465371Completed349Est. Jan 2022
NCT03390491Completed160Est. Jul 2021
+1 more trials
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
MemantinePhase 11 trial
Active Trials
NCT04789915Recruiting46Est. Dec 2026
Eppendorf
EppendorfGermany - Hamburg
2 programs
Goals in FocusN/A1 trial
peer supportN/A1 trial
Active Trials
NCT05252039Recruiting30Est. Dec 2024
NCT02276469Completed200Est. Dec 2014
Otsuka
OtsukaJapan - Tokushima
1 program
BrexpiprazoleN/ASmall Molecule1 trial
Active Trials
NCT05962216Recruiting40Est. Dec 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Cognitive RemediationN/A1 trial
Active Trials
NCT04103775Terminated40Est. Jan 2021
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Family Focused TreatmentN/A1 trial
Active Trials
NCT01907282Completed129Est. Jan 2013
Genomics
GenomicsUK - Oxford
1 program
Genetic: Genomic sequencing and molecular diagnostic results, if any.N/A1 trial
Active Trials
NCT05457140Recruiting15Est. Aug 2026
MSD
MSDIreland - Ballydine
1 program
SCH 900460N/A1 trial
Active Trials
NCT00780585Completed95Est. Jan 2009
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
SCH 900460N/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
SCH 900460N/A
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
TelehealthN/A1 trial
Active Trials
NCT04277585Completed2Est. Sep 2020
Verona Pharma
Verona PharmaUK - London
1 program
Treatment As UsualN/A1 trial
Active Trials
NCT01436331Completed626Est. May 2012
Young BioPharma
Young BioPharmaMA - Lowell
1 program
oral melatonin tabletsN/A1 trial
Active Trials
NCT03826563Completed21Est. Apr 2023
Sandoz
SandozAustria - Kundl
1 program
Haloperidol 10 mg TabletsPHASE_11 trial
Active Trials
NCT00946491Completed30Est. May 1987

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Cognition TherapeuticsCBD 100 mg/mL Oral Solution
Laza MedicalAspirin
Alliance Pharmaceuticalsceftriaxone
LundbeckMemantine
Innovation PharmaceuticalsBehavioral/Attitudinal OnTrack Role-Playing Game
SandozHaloperidol 10 mg Tablets
Alliance PharmaceuticalsCare Coordination
OtsukaBrexpiprazole
GenomicsGenetic: Genomic sequencing and molecular diagnostic results, if any.
EppendorfGoals in Focus
Human BioSciencesTelehealth
Colorado TherapeuticsCognitive Remediation
Young BioPharmaoral melatonin tablets
Innovation PharmaceuticalsOnTrack>TheGame
Innovation PharmaceuticalsCSC OnDemand Training Intervention

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 2,560 patients across 21 trials

NCT06778564Cognition TherapeuticsCBD 100 mg/mL Oral Solution

Stratification and Treatment in Early Psychosis Study - ENHANCE

Start: Feb 2026Est. completion: Feb 2029250 patients
Phase 3Not Yet Recruiting
NCT02685748Laza MedicalAspirin

Aspirin in Young Psychotic Patients

Start: Jul 2017Est. completion: Dec 201960 patients
Phase 2/3Completed
NCT00591318Alliance Pharmaceuticalsceftriaxone

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

Start: Oct 2007Est. completion: Mar 201112 patients
Phase 1/2Terminated
NCT04789915LundbeckMemantine

Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

Start: May 2021Est. completion: Dec 202646 patients
Phase 1Recruiting
NCT02415764Innovation PharmaceuticalsBehavioral/Attitudinal OnTrack Role-Playing Game

OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant

Start: Jun 2015Est. completion: Mar 201619 patients
Phase 1Completed
NCT00946491SandozHaloperidol 10 mg Tablets

To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers

Start: Apr 1987Est. completion: May 198730 patients
Phase 1Completed
NCT06071858Alliance PharmaceuticalsCare Coordination

Enhanced Coordinated Specialty Care for Early Psychosis

Start: Feb 2024Est. completion: Oct 2028350 patients
N/ARecruiting
NCT05962216OtsukaBrexpiprazole

Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders

Start: Jul 2023Est. completion: Dec 202640 patients
N/ARecruiting
NCT05457140GenomicsGenetic: Genomic sequencing and molecular diagnostic results, if any.

Multiomic Diagnostics in Youth With Psychosis

Start: Oct 2022Est. completion: Aug 202615 patients
N/ARecruiting
NCT05252039EppendorfGoals in Focus

Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis

Start: Mar 2020Est. completion: Dec 202430 patients
N/ARecruiting
NCT04277585Human BioSciencesTelehealth

Improving Access to Early Psychosis Coordinated Specialty Care

Start: Sep 2019Est. completion: Sep 20202 patients
N/ACompleted
NCT04103775Colorado TherapeuticsCognitive Remediation

Mechanisms of Cognitive Change

Start: Sep 2019Est. completion: Jan 202140 patients
N/ATerminated
NCT03826563Young BioPharmaoral melatonin tablets

Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms

Start: Jan 2019Est. completion: Apr 202321 patients
N/ACompleted
NCT03390491Innovation PharmaceuticalsOnTrack>TheGame

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

Start: Nov 2018Est. completion: Jul 2021160 patients
N/ACompleted
NCT03465371Innovation PharmaceuticalsCSC OnDemand Training Intervention

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

Start: Oct 2018Est. completion: Jan 2022349 patients
N/ACompleted
NCT03610087Alliance PharmaceuticalsLow Intensity Intervention

Technology-Enabled Collaborative Care for Youth

Start: Jul 2018Est. completion: Jun 202070 patients
N/ACompleted
NCT02933567Innovation PharmaceuticalsCSC OnDemand

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

Start: Nov 2016Est. completion: Aug 201716 patients
N/ACompleted
NCT02276469Eppendorfpeer support

Peer Support for Severe Mental Disorders

Start: Jul 2011Est. completion: Dec 2014200 patients
N/ACompleted
NCT01436331Verona PharmaTreatment As Usual

A Large Pragmatic Cluster Randomized Controlled Trial of a Multi-element Psychosocial Intervention for Early Psychosis

Start: Apr 2010Est. completion: May 2012626 patients
N/ACompleted
NCT01907282Angeles TherapeuticsFamily Focused Treatment

Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis

Start: Jan 2010Est. completion: Jan 2013129 patients
N/ACompleted
NCT00780585MSDSCH 900460

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Start: Apr 2007Est. completion: Jan 200995 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
5 actively recruiting trials targeting 2,560 patients
17 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.